BioCryst Pharmaceuticals (BCRX) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 11, 2026, at corporate headquarters in Durham, NC.

• Shareholders are invited to vote on key proposals, including director elections and executive compensation.

• Proxy materials are available online, with options for paper or email copies upon request.

Voting matters and shareholder proposals

• Election of three directors to serve until the 2029 Annual Meeting.

• Ratification of Ernst & Young LLP as independent auditors for 2026.

• Advisory vote on executive compensation (say-on-pay).

• Approval of an amended and restated Stock Incentive Plan, increasing available shares.

• Authorization for proxy holders to vote on other business as may arise.

Board of directors and corporate governance

• Director nominees are Theresa M. Heggie, Amy E. McKee, M.D., and Jon P. Stonehouse.

• Each nominee is proposed to serve a term ending at the 2029 Annual Meeting.